What Pacira BioSciences, Inc. does.

Pacira BioSciences, Inc., a Delaware corporation, is the holding company for our California operating subsidiary named Pacira Pharmaceuticals, Inc. In March 2007, we acquired Pacira Pharmaceuticals, Inc. from SkyePharma Holdings, Inc. (now Vectura Group Limited, a subsidiary of Molex Asia Holdings, Ltd.), or Skyepharma (the “Skyepharma Acquisition”). In April 2019, we acquired MyoScience, Inc., a privately held medical technology company (the “MyoScience Acquisition”), in November 2021, we acquired Flexion Therapeutics, Inc., or Flexion, a publicly traded biopharmaceutical company (the “Flexion Acquisition”) and in February 2025, we acquired GQ Bio Therapeutics GmbH, or GQ Bio, a privately-held biopharmaceutical company (the “GQ Bio Acquisition”). Unless the context requires otherwise, references to “Pacira,” “we,” the “Company,” the “Registrant,” “us” and “our” in this Annual Report refers to Pacira BioSciences, Inc., a Delaware corporation, and its subsidiaries.

We were incorporated in Delaware under the name Blue Acquisition Corp. in December 2006 and changed our name to Pacira, Inc. in June 2007. In October 2010, we changed our name to Pacira Pharmaceuticals, Inc. and in April 2019, we changed our name to Pacira BioSciences, Inc. Our principal executive offices and corporate headquarters are located in Brisbane, California.

Revenue and profit, by fiscal year.

More on PCRX.

• Pacira BioSciences, Inc. summary
• Pacira BioSciences, Inc. financial statements
• Pacira BioSciences, Inc. key metrics
• Pacira BioSciences, Inc. health scores and style box
• Pacira BioSciences, Inc. earnings
• Pacira BioSciences, Inc. dividends
• Pacira BioSciences, Inc. valuation
• Pacira BioSciences, Inc. ownership and insiders
• Pacira BioSciences, Inc. peers

Figures from Pacira BioSciences, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.